Abstract:BackgroundThe fixed-dose combination of aspirin (acetylsalicylic acid) 25 mg plus extended-release dipyridamole 200 mg (ASA + ER-DP) is used for long-term secondary stroke prevention in patients who have experienced non-cardioembolic stroke or transient ischemic attack. Although the theoretical risk is low that the antiplatelet activity of ASA + ER-DP will be affected by concomitant use of a proton pump inhibitor (PPI), no formal drug-drug interaction studies have been conducted.ObjectiveThis study aimed to determine whether the PPI omeprazole influences the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of ASA + ER-DP.Study Design and SettingThis was a randomized, open-label, multiple-dose, crossover, drug-drug interaction study carried out in a clinical trial unit.ParticipantsSixty healthy male and female volunteers aged 18–50 years were included in the study.InterventionParticipants were randomized to one of two treatment sequences (ABCD or CDAB), each comprising four 7-day treatments with a washout of ≥14 days between the second and third treatments. Treatment A = ASA + ER-DP 25 mg/200 mg (Aggrenox®) twice daily (BID) alone; B = ASA + ER-DP 25 mg/200 mg BID + omeprazole (Prilosec®) 80 mg once daily (QD) following ASA + ER-DP alone for 7 days; C = omeprazole 80 mg QD alone; D = omeprazole 80 mg QD + ASA + ER-DP 25 mg/200 mg BID following omeprazole alone for 7 days.Main Outcome MeasuresThe main outcome measures were systemic PK exposure to ER-DP and ASA inhibition of arachidonic acid-induced platelet aggregation.ResultsSystemic exposure to ER-DP was similar with and without omeprazole, based on steady-state area under the concentration-time curve (AUC) from 0 to 12 h (AUC0–12,ss, ng·h/mL) and maximum plasma concentration (Cmax,ss, ng/mL). For the treatment comparison D versus A, the percent mean ratios were 96.38 (90 % confidence interval [CI] 90.96–102.13) for AUC0–12,ss and 92.03 (86.95–97.40) for Cmax,ss. The ER-DP concentration versus time profiles were nearly superimposable. There was no effect on the PDs of the ASA component: the extent of ASA inhibition of arachidonic acid-induced platelet aggregation was almost identical with and without omeprazole, with a percent mean ratio for treatment D versus A = 99.02 (90 % CI 98.32–99.72) at 4 h after last dose. All treatments were well tolerated.ConclusionThe PK and PD behavior of ASA + ER-DP was not altered by concurrent administration of omeprazole.

Interaction of omeprazole with enteric-coated salicylate tablets

Effect of Omeprazole in treating peptic ulcers of children

Kinetics of Omeprazole Release from Enteric Dosage Forms of Different Manufacturers

Study on Stability of Omeprazole for Injection

Kinetics of aspirin, salicylic acid, and salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions.

Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and Cdna-Expressed Cytochrome P450 Isozymes

Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole.

Pharmacokinetics and 24-Hour Intragastric Ph Monitoring after Venous Infusion of Omeprazole in Healthy Subjects

ABSORPTION AND METABOLISM OF ASPIRIN ADMINISTERED IN ENTERIC-COATED TABLETS.

Oral Bioavailability and Pharmacokinetics of Sildenafil Orally Disintegrating Tablets under Various Gastric pH Levels Following Administration of Omeprazole in Rats

Factors Contributing to Drug Release From Enteric-Coated Omeprazole Capsules: An In Vitro and In Vivo Pharmacokinetic Study and IVIVC Evaluation in Beagle Dogs

Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

The Effect of Low-Dose Omeprazole on 24-Hour Intragastric Ph in Healthy Human Subjects

Towards a Better Understanding of the Post-Gastric Behavior of Enteric-Coated Formulations

Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated Esomeprazole

Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects

Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillus acidophilus on the metabolism of Olsalazine in ulcerative colitis rats

Application of a Radiotelemetric System to Evaluate the Performance of Enteric Coated and Plain Aspirin Tablets

Efficacy of Rabeprazole Versus Omerpazole for Acid Suppression in Patients with Duodenal Ulcer: a Multicenter, Randomized, Double-Blind Clinical Trial